Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 925 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 925 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50. Following the completion of the sale, the chief accounting officer now directly owns 54,002 shares of the company’s stock, valued at approximately $1,022,797.88. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sandra Calvin also recently made the following trade(s):

• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Trading Up 6.9 %

Shares of NASDAQ:TVTX opened at $20.81 on Friday. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -4.57 and a beta of 0.70. The business’s 50 day moving average price is $18.28 and its 200-day moving average price is $14.79. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.89.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The company’s revenue was up 69.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.17) earnings per share. On average, equities research analysts forecast that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. acquired a new position in shares of Travere Therapeutics during the second quarter valued at approximately $343,000. XTX Topco Ltd increased its position in shares of Travere Therapeutics by 110.5% during the second quarter. XTX Topco Ltd now owns 54,262 shares of the company’s stock worth $446,000 after purchasing an additional 28,480 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Travere Therapeutics during the second quarter worth approximately $117,000. DRW Securities LLC acquired a new position in Travere Therapeutics in the 2nd quarter valued at $95,000. Finally, Bank of Montreal Can purchased a new position in Travere Therapeutics in the 2nd quarter valued at $625,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TVTX. Bank of America boosted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Guggenheim increased their price target on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Barclays lifted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Canaccord Genuity Group lowered their target price on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Finally, Citigroup reduced their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.